Phenotypes Associated with This Genotype

Genotype
MGI:5759821

• Allelic Composition: Trp53^tm3Tyj/Trp53⁺; Tg(Wap-cre)11738Mam/0
• Genetic Background: involves: 129S4/SvJae * C57BL/6 * SJL

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

neoplasm

increased mammary gland tumor incidence ( J:101617 )

• 7 of 8 mice develop one or more tumors of the mammary gland after the first pregnancy

• mean latency time for spontaneous mammary tumor development is 19.7 +/- 8.6 weeks

• mammary tumors of both untreated and DMBA-treated mice are heterogeneous, including frequent adenocarcinomas, solid carcinomas, papillary carcinomas, and adenosquamous carcinomas, carcinosarcomas and sarcomas

• 67% of mammary tumors from untreated and DMBA-treated mice are estrogen receptor alpha-positive

increased mammary adenocarcinoma incidence ( J:101617 )

increased incidence of tumors by chemical induction ( J:101617 )

• 40% of females exposed to DMBA for 6 weeks develop mammary tumors, with a mean latency time of 8.5 +/- 4.7 weeks

• females exposed to DMBA also develop lymphomas, ovary, lung, stomach, uterus and skin tumors

increased lymphoma incidence ( J:101617 )

• some mice develop an additional lymphoma

increased sarcoma incidence ( J:101617 )

• some mice develop an additional sarcoma in the abdomen

increased lung tumor incidence ( J:101617 )

• some mice develop an additional tumor of the lung

mortality/aging

premature death ( J:101617 )

• premature death, with only 2 of 11 mice surviving past 78 weeks

endocrine/exocrine glands

increased mammary gland tumor incidence ( J:101617 )

• 7 of 8 mice develop one or more tumors of the mammary gland after the first pregnancy

• mean latency time for spontaneous mammary tumor development is 19.7 +/- 8.6 weeks

• mammary tumors of both untreated and DMBA-treated mice are heterogeneous, including frequent adenocarcinomas, solid carcinomas, papillary carcinomas, and adenosquamous carcinomas, carcinosarcomas and sarcomas

• 67% of mammary tumors from untreated and DMBA-treated mice are estrogen receptor alpha-positive

increased mammary adenocarcinoma incidence ( J:101617 )

homeostasis/metabolism

increased incidence of tumors by chemical induction ( J:101617 )

• 40% of females exposed to DMBA for 6 weeks develop mammary tumors, with a mean latency time of 8.5 +/- 4.7 weeks

• females exposed to DMBA also develop lymphomas, ovary, lung, stomach, uterus and skin tumors

integument

increased mammary gland tumor incidence ( J:101617 )

• 7 of 8 mice develop one or more tumors of the mammary gland after the first pregnancy

• mean latency time for spontaneous mammary tumor development is 19.7 +/- 8.6 weeks

• mammary tumors of both untreated and DMBA-treated mice are heterogeneous, including frequent adenocarcinomas, solid carcinomas, papillary carcinomas, and adenosquamous carcinomas, carcinosarcomas and sarcomas

• 67% of mammary tumors from untreated and DMBA-treated mice are estrogen receptor alpha-positive

increased mammary adenocarcinoma incidence ( J:101617 )

respiratory system

increased lung tumor incidence ( J:101617 )

• some mice develop an additional tumor of the lung

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
breast cancer		DOID:1612	OMIM:114480	J:101617